EW
Income statement / Annual
Last year (2023), Edwards Lifesciences Corporation's total revenue was $6.00 B,
an increase of 11.56% from the previous year.
In 2023, Edwards Lifesciences Corporation's net income was $1.40 B.
See Edwards Lifesciences Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$6.00 B
|
$5.38 B
|
$5.23 B
|
$4.39 B
|
$4.35 B
|
$3.72 B
|
$3.44 B
|
$2.96 B
|
$2.49 B
|
$2.32 B
|
| Cost of Revenue |
$1.38 B |
$1.08 B |
$1.25 B |
$1.08 B |
$1.11 B |
$939.40 M |
$875.30 M |
$797.40 M |
$617.20 M |
$625.60 M |
| Gross Profit |
$4.63 B |
$4.30 B |
$3.98 B |
$3.31 B |
$3.23 B |
$2.78 B |
$2.56 B |
$2.17 B |
$1.88 B |
$1.70 B |
| Gross Profit Ratio |
0.77 |
0.8 |
0.76 |
0.75 |
0.74 |
0.75 |
0.75 |
0.73 |
0.75 |
0.73 |
| Research and Development
Expenses |
$1.07 B
|
$945.20 M
|
$903.10 M
|
$760.70 M
|
$752.70 M
|
$622.20 M
|
$552.60 M
|
$443.30 M
|
$383.10 M
|
$346.50 M
|
| General & Administrative
Expenses |
$1.82 B
|
$1.57 B
|
$1.49 B
|
$0.00
|
$0.00
|
$1.09 B
|
$984.70 M
|
$904.70 M
|
$850.70 M
|
$858.00 M
|
| Selling & Marketing
Expenses |
$1.20 M
|
$1.10 M
|
-$300,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$1.82 B
|
$1.57 B
|
$1.49 B
|
$1.23 B
|
$1.24 B
|
$1.09 B
|
$984.70 M
|
$904.70 M
|
$850.70 M
|
$858.00 M
|
| Other Expenses |
$3.40 M |
$2.60 M |
$12.70 M |
$11.50 M |
$8.20 M |
$4.00 M |
-$8.20 M |
-$4.90 M |
-$4.00 M |
-$7.70 M |
| Operating Expenses |
$2.90 B |
$2.51 B |
$2.40 B |
$1.99 B |
$1.99 B |
$1.71 B |
$1.54 B |
$1.35 B |
$1.23 B |
$1.20 B |
| Cost And Expenses |
$4.28 B |
$3.59 B |
$3.65 B |
$3.07 B |
$3.11 B |
$2.65 B |
$2.41 B |
$2.15 B |
$1.85 B |
$1.83 B |
| Interest Income |
$67.20 M |
$35.50 M |
$17.40 M |
$23.40 M |
$11.50 M |
$32.00 M |
$20.30 M |
$10.80 M |
$7.90 M |
$6.40 M |
| Interest Expense |
$17.60 M |
$19.20 M |
$18.40 M |
$15.80 M |
$20.70 M |
-$2.10 M |
$2.90 M |
$8.40 M |
$9.30 M |
$10.80 M |
| Depreciation &
Amortization |
$145.00 M
|
$166.80 M
|
$163.30 M
|
$135.40 M
|
$114.60 M
|
$77.40 M
|
$81.90 M
|
$71.20 M
|
$65.80 M
|
$68.60 M
|
| EBITDA |
$1.95 B
|
$1.83 B
|
$1.48 B
|
$1.74 B
|
$1.33 B
|
$1.39 B
|
$999.40 M
|
$885.40 M
|
$649.70 M
|
-$176.90 M
|
| EBITDA Ratio |
0.32 |
0.34 |
0.28 |
0.4 |
0.31 |
0.37 |
0.29 |
0.3 |
0.26 |
-0.08 |
| Operating Income Ratio
|
0.26
|
0.32
|
0.26
|
0.37
|
0.26
|
0.2
|
0.3
|
0.26
|
0.26
|
0.21
|
| Total Other
Income/Expenses Net |
-$181.30 M
|
$18.90 M
|
$353.50 M
|
-$711.70 M
|
$19.70 M
|
-$313.40 M
|
$15.10 M
|
-$72.00 M
|
-$11.00 M
|
$662.00 M
|
| Income Before Tax |
$1.60 B |
$1.77 B |
$1.70 B |
$916.70 M |
$1.17 B |
$761.40 M |
$1.03 B |
$737.90 M |
$622.40 M |
$1.14 B |
| Income Before Tax Ratio
|
0.27
|
0.33
|
0.33
|
0.21
|
0.27
|
0.2
|
0.3
|
0.25
|
0.25
|
0.49
|
| Income Tax Expense |
$198.70 M |
$245.50 M |
$198.90 M |
$93.30 M |
$119.60 M |
$39.20 M |
$412.80 M |
$168.40 M |
$127.50 M |
$332.90 M |
| Net Income |
$1.40 B |
$1.52 B |
$1.50 B |
$823.40 M |
$1.05 B |
$722.20 M |
$622.10 M |
$569.50 M |
$494.90 M |
$811.10 M |
| Net Income Ratio |
0.23 |
0.28 |
0.29 |
0.19 |
0.24 |
0.19 |
0.18 |
0.19 |
0.2 |
0.35 |
| EPS |
2.31 |
2.46 |
2.41 |
1.32 |
1.68 |
1.15 |
0.98 |
0.89 |
0.77 |
1.27 |
| EPS Diluted |
2.3 |
2.44 |
2.38 |
1.3 |
1.64 |
1.13 |
0.96 |
0.87 |
0.75 |
1.25 |
| Weighted Average Shares
Out |
$606.70 M
|
$619.00 M
|
$623.30 M
|
$622.60 M
|
$624.90 M
|
$627.60 M
|
$632.70 M
|
$639.00 M
|
$646.50 M
|
$639.00 M
|
| Weighted Average Shares
Out Diluted |
$609.40 M
|
$624.20 M
|
$631.20 M
|
$631.90 M
|
$636.60 M
|
$640.80 M
|
$647.70 M
|
$653.40 M
|
$660.90 M
|
$651.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
